BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-592@pharmaconomics
DTSTAMP:20260707T033837Z
DTSTART;VALUE=DATE:20260323
DTEND;VALUE=DATE:20260324
SUMMARY:INSM Phase 3 — ARIKAYCE
DESCRIPTION:Phase 3 trial results for ARIKAYCE in Mycobacterium avium complex (MAC) lung infection are due Mar 23\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1104506/000114036126010651/ef20068516_ex99-2.htm\n\nTrack it: https://pharmaconomics.com/e/592
URL:https://pharmaconomics.com/e/592
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:INSM catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR